Noven Pharmaceuticals Company Description
Noven Pharmaceuticals makes it easier to get drugs beneath the surface. The company develops drugs using its transdermal drug delivery system, which administers medication through a patch attached to the skin. Noven's hormone replacement therapy patches (including Vivelle-Dot and CombiPatch) treat menopause and osteoporosis. Novogyne Pharmaceuticals, Noven's joint venture with Novartis, markets the products in the US; Novartis markets them in most international markets. Noven also developed Shire's Daytrana patch, used to treat attention deficit hyperactivity disorder (ADHD). In 2007 Noven acquired psychiatric drugmaker JDS Pharmaceuticals, which has become the company's Noven Therapeutics unit.
View the Comprehensive Company Description for Noven Pharmaceuticals
The Company Description provides a historical perspective of Noven Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Noven Pharmaceuticals's evolution in the marketplace.
